Amello Jason
SEC-identified person · CIK 1451805 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Tscan Therapeutics, Inc. TCRX | Chief Financial Officer | filed 2024–2026 |
| Candel Therapeutics, Inc. CADL | Chief Financial Officer | filed 2022–2023 |
| Pharmafrontiers Corp. pftr.ob | Director | filed 2017–2023 |
| Akebia Therapeutics, Inc. AKBA | SVP, CFO & Treasurer | filed 2014–2020 |
| Ziopharm Oncology INC ZIOP | Executive Vice President & CFO | filed 2012–2013 |
| Genzyme Corp u4yfvwk$ | CorpContrllr,ChiefAccntOfficer | filed 2008–2011 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.